
    
      To evaluate the efficacy and safety of Pembrolizumab + Pemetrexed in elderly patients with
      non-squamous non-small cell lung cancer with Programmed cell death (PD) -ligand1 (L1) tumor
      proportion score (TPS) of less than 50%.Primary endpoint is overall response rate and
      secondary endpoints are progression free survival (PFS), 1 year PFS rate, overall survival
      and adverse event.
    
  